Table 1.

Baseline characteristics before start of treatment

CharacteristicTotal (n=48)PLA2R Antibody Negative (n=14)PLA2R Antibody Positive (n=34)P Value
Men (n)3711260.88
Age (yr)55 (34–75)57 (38–75)54 (34–74)0.89
Serum creatinine (mg/dl)1.60 (0.98–3.37)1.72 (1.24–3.37)1.54 (0.98–3.14)0.19
Serum albumin (g/dl)2.6 (1.5–3.9)2.9 (1.5–3.9)2.4 (1.8–3.5)0.09
Protein/creatinine ratio (g/g)10.1 (3.2–25.2)7.9 (5.1–23.5)10.5 (3.2–25.2)0.10
SI0.34 (0.12–0.53)0.29 (0.12–0.51)0.35 (0.18–0.53)0.07
eGFR (ml/min per 1.73 m2)a47 (21–96)41 (21–91)48 (21–96)0.50
PLA2R antibody (U/ml)216 (1–16,260)9 (1–38)428 (41–16,260)<0.01
Severe nephrosis as reason for start treatment (n)2020.35
MMF (n)227150.71
Cyclophosphamide (n)26719
Recurrent episode at presentation (n)9450.26
Previous immunosuppressive therapy (n)4/92/42/50.33
Time from baseline to start treatment (mo)5 (1–26)4 (1–24)7 (1–26)0.40
Follow-up duration (mo)52 (0–60)60 (0–60)47 (0–60)0.65
Outcome
 Persistent remission217140.58
 Relapse175120.98
 Persistent proteinuria2110.51
 Immunosuppressive therapy3030.25
 Dead5140.63
  • Unless otherwise noted, values are given as median and range. PLA2R, phospholipase A2 receptor; SI, selectivity index (ratio clearance IgG/clearance transferrin); MMF, mycophenolate mofetil.

  • a eGFR was calculated with the Modification of Diet in Renal Disease-6 formula.